120 related articles for article (PubMed ID: 37329258)
1. Development and validation of nomogram to improve the specificity of multiparametric MRI for clinically significant prostate cancer.
Shiekh M; Houenstein H; Ramahi YO; Shabir U; Ghadersohi S; Zhu D; Zhu M; Jing Z; Attwood K; Kauffman E; Aboumohamed A; Guru K; Hussein AA
Int J Urol; 2023 Oct; 30(10):876-882. PubMed ID: 37329258
[TBL] [Abstract][Full Text] [Related]
2. Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region.
Zhou Z; Liang Z; Zuo Y; Zhou Y; Yan W; Wu X; Ji Z; Li H; Hu M; Ma L
Prostate; 2022 Apr; 82(5):556-565. PubMed ID: 35098557
[TBL] [Abstract][Full Text] [Related]
3. Prediction of false-positive PI-RADS 5 lesions on prostate multiparametric MRI: development and internal validation of a clinical-radiological characteristics based nomogram.
Cheng Y; Fan B; Fu Y; Yin H; Lu J; Li D; Li X; Qiu X; Guo H
BMC Urol; 2024 Apr; 24(1):76. PubMed ID: 38566091
[TBL] [Abstract][Full Text] [Related]
4. An integrated nomogram combining deep learning, Prostate Imaging-Reporting and Data System (PI-RADS) scoring, and clinical variables for identification of clinically significant prostate cancer on biparametric MRI: a retrospective multicentre study.
Hiremath A; Shiradkar R; Fu P; Mahran A; Rastinehad AR; Tewari A; Tirumani SH; Purysko A; Ponsky L; Madabhushi A
Lancet Digit Health; 2021 Jul; 3(7):e445-e454. PubMed ID: 34167765
[TBL] [Abstract][Full Text] [Related]
5. Predicting Benign Prostate Pathology on Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Men with a Prior Negative 12-core Systematic Biopsy: External Validation of a Prognostic Nomogram.
Bjurlin MA; Renson A; Rais-Bahrami S; Truong M; Rosenkrantz AB; Huang R; Taneja SS
Eur Urol Focus; 2019 Sep; 5(5):815-822. PubMed ID: 29802053
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Accuracy and Prognostic Value of Serial Prostate Multiparametric Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer.
Chu CE; Cowan JE; Lonergan PE; Washington SL; Fasulo V; de la Calle CM; Shinohara K; Westphalen AC; Carroll PR
Eur Urol Oncol; 2022 Oct; 5(5):537-543. PubMed ID: 33483265
[TBL] [Abstract][Full Text] [Related]
7. Risk of Clinically Significant Prostate Cancer Associated With Prostate Imaging Reporting and Data System Category 3 (Equivocal) Lesions Identified on Multiparametric Prostate MRI.
Sheridan AD; Nath SK; Syed JS; Aneja S; Sprenkle PC; Weinreb JC; Spektor M
AJR Am J Roentgenol; 2018 Feb; 210(2):347-357. PubMed ID: 29112469
[TBL] [Abstract][Full Text] [Related]
8. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
[TBL] [Abstract][Full Text] [Related]
9. Targeted MRI/TRUS fusion-guided biopsy in men with previous prostate biopsies using a novel registration software and multiparametric MRI PI-RADS scores: first results.
Tewes S; Hueper K; Hartung D; Imkamp F; Herrmann TR; Weidemann J; Renckly S; Kuczyk MA; Wacker F; Peters I
World J Urol; 2015 Nov; 33(11):1707-14. PubMed ID: 25774003
[TBL] [Abstract][Full Text] [Related]
10. Predictive clinical features for negative histopathology of MRI/Ultrasound-fusion-guided prostate biopsy in patients with high likelihood of cancer at prostate MRI: Analysis from a urologic outpatient clinic1.
Apfelbeck M; Pfitzinger P; Bischoff R; Rath L; Buchner A; Mumm JN; Schlenker B; Stief CG; Chaloupka M; Clevert DA
Clin Hemorheol Microcirc; 2020; 76(4):503-511. PubMed ID: 33337358
[TBL] [Abstract][Full Text] [Related]
11. PSA density is complementary to prostate MP-MRI PI-RADS scoring system for risk stratification of clinically significant prostate cancer.
Frisbie JW; Van Besien AJ; Lee A; Xu L; Wang S; Choksi A; Afzal MA; Naslund MJ; Lane B; Wong J; Wnorowski A; Siddiqui MM
Prostate Cancer Prostatic Dis; 2023 Jun; 26(2):347-352. PubMed ID: 35523940
[TBL] [Abstract][Full Text] [Related]
12. Exploration of the diagnostic capacity of PSAMR combined with PI-RADS scoring for clinically significant prostate cancer and establishment and validation of the Nomogram prediction model.
Li D; Zhang L; Xu Y; Wu X; Hua S; Jiang Y; Huang Q; Gao Y
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11309-11317. PubMed ID: 37365430
[TBL] [Abstract][Full Text] [Related]
13. Prostate Health Index Density Outperforms Prostate-specific Antigen Density in the Diagnosis of Clinically Significant Prostate Cancer in Equivocal Magnetic Resonance Imaging of the Prostate: A Multicenter Evaluation.
Chiu PK; Leow JJ; Chiang CH; Mok A; Zhang K; Hsieh PF; Zhu Y; Lam W; Tsang WC; Fan YH; Lin TP; Chan TY; Leung CH; Teoh JY; Chu PS; Zhu G; Ye DW; Wu HC; Tan TW; Tsu JH; Ng CF; Chiong E; Huang CY
J Urol; 2023 Jul; 210(1):88-98. PubMed ID: 37036248
[TBL] [Abstract][Full Text] [Related]
14. Developing a nomogram based on multiparametric magnetic resonance imaging for forecasting high-grade prostate cancer to reduce unnecessary biopsies within the prostate-specific antigen gray zone.
Niu XK; Li J; Das SK; Xiong Y; Yang CB; Peng T
BMC Med Imaging; 2017 Feb; 17(1):11. PubMed ID: 28143433
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla.
Roethke MC; Kuru TH; Schultze S; Tichy D; Kopp-Schneider A; Fenchel M; Schlemmer HP; Hadaschik BA
Eur Radiol; 2014 Feb; 24(2):344-52. PubMed ID: 24196383
[TBL] [Abstract][Full Text] [Related]
16. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
17. Which men with non-malignant pathology at magnetic resonance imaging-targeted prostate biopsy and persistent PI-RADS 3-5 lesions should repeat biopsy?
Castellani D; Pace G; Cecchini S; Franzese C; Cicconofri A; Romagnoli D; Del Rosso A; Possanzini M; Paci E; Dellabella M; Pierangeli T
Urol Oncol; 2022 Oct; 40(10):452.e9-452.e16. PubMed ID: 35871992
[TBL] [Abstract][Full Text] [Related]
18. Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy.
Thaiss WM; Moser S; Hepp T; Kruck S; Rausch S; Scharpf M; Nikolaou K; Stenzl A; Bedke J; Kaufmann S
World J Urol; 2022 Oct; 40(10):2431-2438. PubMed ID: 35922717
[TBL] [Abstract][Full Text] [Related]
19. MRI-Ultrasound Fusion Targeted Biopsy of Prostate Imaging Reporting and Data System Version 2 Category 5 Lesions Found False-Positive at Multiparametric Prostate MRI.
Sheridan AD; Nath SK; Aneja S; Syed JS; Pahade J; Mathur M; Sprenkle P; Weinreb JC; Spektor M
AJR Am J Roentgenol; 2018 May; 210(5):W218-W225. PubMed ID: 29489409
[TBL] [Abstract][Full Text] [Related]
20. PI-RADS v2 and periprostatic fat measured on multiparametric magnetic resonance imaging can predict upgrading in radical prostatectomy pathology amongst patients with biopsy Gleason score 3 + 3 prostate cancer.
Zhai L; Fan Y; Sun S; Wang H; Meng Y; Hu S; Wang X; Yu W; Jin J
Scand J Urol; 2018; 52(5-6):333-339. PubMed ID: 30895901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
